Figure Showing Fusion Detected in a Case of Polymorphous Low Grade Adenocarcinoma

Who would request this test?
   Pathologists, Oncologists, and Head and Neck Surgeons

How to order the test?
   Contact Client Services – 866-844-2522 or
   Refer to the Salivary Gland Tumor Fusion Panel with Interpretation test entry in the UIDL Test Directory

Testing for salivary gland tumor (SGT) associated RNA Fusions is available in the University of Iowa Hospitals and Clinics Molecular Pathology Laboratory.

Accurate diagnosis of salivary gland tumors can be challenging due to the diversity of these tumors, morphologic overlap between different tumor types, and the limited immunohistochemistry for differential diagnosis. It is even more challenging for fine needle aspirate diagnosis. Recurrent genomic rearrangements resulting in gene fusions are identified in increasing numbers of SGTs, which could serve as diagnostic and prognostic markers.

The panel is an RNA-based next-generation sequencing assay that could detect fusion transcripts arising from the rearranged genes. It targets gene fusion products of 14 genes and single nucleotide variants in PRKD1 codon 710 and HRAS codon 61 that are commonly associated with salivary gland tumors.

Epic Order Code: LAB8690

Method: Massively parallel sequencing or next generation sequencing from specimen RNA. Testing is batched. Turn around time is 7-10 days.

Specimen type: formalin-fixed, paraffin-embedded tissue or fine needle aspirate smears; minimal requirement: 2000 tumor cells,  ≥20% tumor cells.